VistaGen to Participate at William Blair Biotech Focus Conference 2022

Rhea-AI Summary

VistaGen Therapeutics (Nasdaq: VTGN) announced that CEO Shawn Singh will participate in a panel on unmet needs in neuropsychiatry at the William Blair Biotech Focus Conference on July 13, 2022, at 9:00 a.m. ET. He will also engage in one-on-one investor meetings and a recorded fireside chat. VistaGen focuses on developing fast-acting treatments for anxiety and depression, with its lead candidate PH94B in Phase 3 trials. Topline results are expected in 2022, potentially leading to the first FDA-approved acute anxiety treatment for social anxiety disorder.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that Chief Executive Officer Shawn Singh will participate in a panel discussing unmet needs and novel therapies in neuropsychiatry at the William Blair Biotech Focus Conference on Wednesday, July 13, 2022 at 9:00 a.m. Eastern Time.

In addition to participating in the panel, Mr. Singh will host one-on-one meetings with investors at the conference and will take part in a recorded fireside chat, available on demand to all registered conference attendees. A link to the recorded presentation may be found on the ‘Events’ page within the ‘Investors’ section of the VistaGen website, beginning Monday, July 11, 2022, at 9:00 a.m. Eastern Time.

About VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with topline results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.VistaGen.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by VistaGen and its management, are inherently uncertain. The Company’s actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties relating to delays in launching, conducting and/or completing ongoing and planned clinical trials, including delays due to the impact of the ongoing COVID-19 pandemic; fluctuating costs of materials and other resources required to conduct the Company’s ongoing and/or planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; adverse healthcare reforms and changes of laws and regulations; manufacturing and marketing risks, which may include, but are not limited to, unavailability of or delays in delivery of raw materials for manufacture of the Company’s CNS drug candidates due to the ongoing COVID-19 pandemic or otherwise; inadequate and/or untimely supply of one or more of the Company’s CNS drug candidates to meet demand; entry of competitive products; and other technical and unexpected hurdles in the development, manufacture and commercialization of the Company’s CNS drug candidates; and the risks more fully discussed in the section entitled "Risk Factors" in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). The Company’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005257/en/

Investors:

Mark Flather

Vice President, Investor Relations

(650) 577-3617

mflather@vistagen.com

Media:

Nate Hitchings

SKDK

nhitchings@skdknick.com

Source: VistaGen Therapeutics, Inc.

FAQ

What is VistaGen Therapeutics' main focus?

VistaGen Therapeutics focuses on transforming treatments for anxiety, depression, and other central nervous system disorders.

When is Shawn Singh speaking at the William Blair Biotech Focus Conference?

Shawn Singh will participate in the conference on July 13, 2022, at 9:00 a.m. ET.

What clinical stage is the PH94B treatment currently in?

PH94B is currently in multiple Phase 3 trials in the U.S.

What are the expected topline results for PH94B?

Topline results for PH94B are anticipated in 2022.

What potential does PH94B hold for anxiety treatment?

If successful, PH94B could become the first FDA-approved, fast-acting treatment for acute anxiety in adults with social anxiety disorder.